Yankee Candle expands leadership team
SOUTH DEERFIELD, Mass. — Yankee Candle has appointed Brad Wolansky to serve in the newly created role of president of direct and chief marketing officer.
Wolansky — who joins the company from the Golf Warehouse, where he served as CEO — is responsible for building the Yankee Candle’s branding efforts across all channels through unique and compelling marketing communications and will lead the company’s digital branding and e-commerce efforts to drive sales. Wolansky will report to Yankee Candle CEO Harlan Kent and have responsibility for the consumer direct, creative, marketing, public relations and social media teams.
Yankee Candle said Wolansky’s appointment is part of a strategic initiative focused on building the company’s brands, expanding the digital platform and accelerating growth of its direct-to-consumer business.
"In the past year, we have energized our Yankee Candle branding effort driven by better understanding our customer and what she wants and needs," Yankee Candle CEO Harlan Kent said. "Part of this strategic effort revolves around bringing in world class direct talent. Brad has successfully grown leading retail brands and is the ideal person to spearhead both our marketing and direct business to help us achieve our growth goals."
FDA approves blood cancer drug
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating multiple myeloma, the agency said Friday.
The FDA announced the approval of South San Francisco, Calif.-based Onyx Pharmaceuticals’ Kyprolis (carfilzomib). The drug is designed for patients with the disease who have received at least two prior therapies, including Takeda Pharmaceutical Co.’s Velcade (bortezomib) and an immunomodulatory therapy. Multiple myeloma, a blood cancer that usually grows in the bone marrow, is expected to be diagnosed in about 21,700 people this year, according to the American Cancer Society, while 10,710 will die from it.
"The approval of Kyprolis provides a treatment option to patients with multiple myeloma whose disease has progressed despite use of available therapies," FDA Office of Hematology and Oncology Products director Richard Pazdur said. "We are encouraged by the continued progress in the development of drugs for multiple myeloma over the past decade, offering improved treatment of this disease."
CVS Caremark research further underscores importance of medication adherence, pharmacists’ role in patients’ lives
WHAT IT MEANS AND WHY IT’S IMPORTANT — Yes, there’s been a lot research and news touting the importance of medication adherence — and there’s a $300 billion reason for that — but this most recent CVS Caremark-sponsored research is one of the first studies that quantifies the impact of medication adherence on worker absenteeism.
(THE NEWS: CVS Caremark research finds link between medication adherence, employee productivity. For the full story, click here)
With such chronic diseases as diabetes, high blood pressure and elevated cholesterol impacting 70% of working-age adults in the United States, it is critical that the message on the importance of medication adherence is heard loud and clear. Just look at the survey results: Employees with chronic conditions who were adherent to their prescribed medications had up to seven fewer days away from work annually (including absenteeism and short-term disability days) than those who were not adherent, the research found. This translated into estimated annual savings of up to nearly $1,700 per adherent employee. That is a significant savings.
Pharmacists do — and must continue to — play an important role in educating patients on the importance of medication adherence as health care continues to face an uphill battle. Just look at diabetes as one example: A disease that costs $174 billion annually, including $116 billion in direct medical expenses.
Nearly 26 million Americans have diabetes, according to estimates from the Centers for Disease Control and Prevention. In addition, an estimated 79 million U.S. adults have prediabetes, a condition in which blood-sugar levels are higher than normal, but not high enough to be diagnosed as diabetes. Prediabetes raises a person’s risk of Type 2 diabetes, heart disease and stroke.
In a study published in 2010, CDC projected that as many as 1-out-of-3 U.S. adults could have diabetes by 2050, if current trends continue.
Then there’s healthcare reform to consider. With the U.S. Supreme Court upholding the constitutionality of the Patient Protection and Affordable Care Act, including the notion that individuals could face federal tax penalties if they failed to purchase some level of health insurance by 2014, that could put as many as 40 million uninsured Americans into the coverage rolls — and potentially into prescription drug coverage.
It will drive a good number of patients to medical homes, and in theory, significantly increase the demand for maintenance prescriptions and other preventative or chronic healthcare services.
The bottom line is that this most recent CVS Caremark research further underscores the importance of medication adherence and the critical role that pharmacists play in helping their patients live healthier lives.
What are your thoughts on this topic and have you experienced this issue among employees within your own company?